Overview

A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants

Status:
Not yet recruiting
Trial end date:
2022-09-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of aticaprant on QT/ QT interval corrected for heart rate (HR) (QTc) intervals and electrocardiogram (ECG) morphology at therapeutic and supratherapeutic exposures in healthy adult participants.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Aticaprant
Moxifloxacin